Coya Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Coya Therapeutics, Inc. (COYA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 922.43 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 35.00K shares.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 887.43K shares, a 4.50% increase year-over-year.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 75.00K shares, a 141.94% increase year-over-year.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 924.20K shares, a 16.08% decline from fiscal 2024.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.10M shares, a 44.91% increase from fiscal 2023.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 760.04K shares, a 401.90% increase from fiscal 2022.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 151.43K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 35.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 922.43K shares 10-Q · filed 2026-08-11 | 922.43K shares derived: sum of 3 quarters · filed 2026-08-11 | 997.43K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 887.43K shares 10-Q · filed 2026-05-12 | 887.43K shares derived: sum of 2 quarters · filed 2026-05-12 | 962.43K shares derived: sum of 3 quarters · filed 2026-05-12 | 962.43K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 75.00K shares derived: sum of 2 quarters · filed 2026-03-16 | 75.00K shares derived: sum of 3 quarters · filed 2026-03-16 | 924.20K shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 75.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 75.00K shares derived: sum of 2 quarters · filed 2025-11-12 | 924.20K shares 10-Q · filed 2025-11-12 | 924.20K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 849.20K shares 10-Q · filed 2025-08-12 | 849.20K shares derived: sum of 3 quarters · filed 2025-08-12 | 880.20K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 849.20K shares 10-Q · filed 2025-05-13 | 849.20K shares derived: sum of 2 quarters · filed 2025-05-13 | 880.20K shares derived: sum of 3 quarters · filed 2025-05-13 | 1.38M shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 31.00K shares derived: sum of 2 quarters · filed 2025-03-18 | 534.93K shares derived: sum of 3 quarters · filed 2025-03-18 | 1.10M shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 31.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 534.93K shares derived: sum of 2 quarters · filed 2024-11-06 | 1.10M shares 10-Q · filed 2024-11-06 | 1.10M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 503.93K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 1.07M shares 10-Q · filed 2024-08-12 | 1.07M shares derived: sum of 3 quarters · filed 2024-08-12 | 1.18M shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 566.41K shares 10-Q · filed 2024-05-09 | 566.41K shares derived: sum of 2 quarters · filed 2024-05-09 | 675.48K shares derived: sum of 3 quarters · filed 2024-05-09 | 790.48K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 109.07K shares derived: sum of 2 quarters · filed 2024-03-19 | 224.07K shares derived: sum of 3 quarters · filed 2024-03-19 | 760.04K shares 10-K · filed 2024-03-19 |
| 2023-09-30 | 109.07K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 224.07K shares derived: sum of 2 quarters · filed 2023-11-08 | 760.04K shares 10-Q · filed 2023-11-08 | |
| 2023-06-30 | 115.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 650.97K shares 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | 535.97K shares 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | 151.43K shares 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |